)
Edge26 Jun 2026
The Universal Language: Inventing the Barcode
How lines in the sand on a Miami beach became the most scanned symbol in human history, and why it took decades for anyone to care.
Crescent Biopharma
Crescent Biopharma (CBIO) investor relations material
Crescent Biopharma Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary1 Jul, 2026
Company overview and business model
Clinical-stage biotechnology company focused on transformative oncology therapies, aiming to become a leading player in cancer treatment.
Portfolio strategy includes a lead PD-1 x VEGF bispecific antibody (CR-001) and a pipeline of antibody drug conjugates (ADCs).
Global Phase 1/2 trials for CR-001 and CR-003 initiated in 2026, with additional ADC trials planned.
Resulted from a reverse recapitalization and re-domiciled to the Cayman Islands in June 2025.
Financial performance and metrics
As of March 31, 2026, historical net tangible book value was $183.8 million, or $6.67 per share.
After a $200 million offering at $18.00 per share, as-adjusted net tangible book value would be $377.3 million, or $9.75 per share.
Immediate dilution to new investors estimated at $8.25 per share.
Use of proceeds and capital allocation
Net proceeds from securities sales will be used for general corporate purposes, including research and development and working capital.
Management retains broad discretion over allocation and timing of expenditures.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Crescent Biopharma
- Four clinical studies launching this year set up a data-rich 2027 for next-gen oncology assets.CBIO
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA26 Jun 2026 - CR-001 and ADC combinations target a $100B+ oncology market, with pivotal data expected in 2027.CBIOGoldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026
- Landmark data validate PD-1/VEGF bispecifics, driving a paradigm shift in immuno-oncology.CBIOJefferies Global Healthcare Conference 20264 Jun 2026
- Directors elected, auditor ratified, and executive compensation approved with annual advisory votes.CBIOAGM 20262 Jun 2026
- Advancing next-gen IO and ADC therapies with major data readouts and strong cash runway into 2028.CBIOStifel 2026 Targeted Oncology Virtual Forum22 May 2026
- Global oncology programs target robust 2027 data, leveraging rapid development and broad indications.CBIOBank of America Global Healthcare Conference 202614 May 2026
- Net loss of $23.3M, $1M revenue, and $189.2M cash runway into 2028 as clinical programs advance.CBIOQ1 202629 Apr 2026
- Election of two Class II directors is up for vote at the June 2026 annual meeting.CBIOProxy filing21 Apr 2026
- Virtual meeting to elect directors, ratify auditor, and approve executive pay and governance.CBIOProxy filing21 Apr 2026
Next Crescent Biopharma earnings date
Q2 202629 Jul, 2026
Crescent Biopharma
Next Crescent Biopharma earnings date
Q2 202629 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage